Saturday 17 October 2026
Export CELU’s income statement to Excel — free account
Celularity, Inc.
CELU Healthcare Biotechnology
Celularity, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $26.6 million, down 51.0% from fiscal 2024. In the quarter to March 2026, revenue fell 66.3%, EPS grew 103.6%, free cash flow grew 148.4% and total debt fell 4.73%, each against the same quarter a year earlier.
1.25
0.08
−6.02%
Follow CELU
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | |
|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
1 | 5 | 4 | 2 | — | — | — | — | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 11.45 | 0.00 | 0.00 | — | — | — |
P/S ratio |
1.07 | 0.84 | 2.19 | 8.80 | 16.09 | 0.00 | — | — | — |
Altman Z-Score |
(15.22) | (10.12) | (12.58) | (1.97) | (2.31) | (2.54) | — | — | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Altman Z″-Score (non-manufacturers) |
(38.41) | (25.61) | (29.80) | (5.11) | (6.14) | (5.89) | — | — | — |
P/Operating CF |
(5.57) | 28.57 | (11.49) | (5.34) | (10.71) | (12.04) | — | — | — |
Beneish M-Score |
(5.93) | (3.40) | (8.28) | — | (1.68) | — | — | — | — |
P/B ratio |
0.00 | 5.15 | 1.22 | 0.79 | 3.45 | 0.00 | — | — | — |
Price to Tangible BV |
0.00 | 0.00 | 2.21 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Sales |
2.64 | 1.61 | 5.05 | 11.67 | 15.81 | 0.00 | — | — | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
EV/Operating CF |
(5.29) | (13.60) | (2.97) | (1.52) | (3.06) | (2.78) | — | — | — |
EV/FCF |
(5.22) | (13.27) | (2.89) | (1.47) | (2.90) | (2.78) | — | — | — |
Quick Ratio |
0.13 | 0.27 | 0.18 | 0.34 | 1.62 | 2.28 | 4.00 | 0.16 | — |
Current Ratio |
0.15 | 0.38 | 0.29 | 0.54 | 2.25 | 2.71 | 4.41 | 0.16 | — |
Net Debt/EBITDA |
(0.77) | (1.37) | (0.55) | (4.11) | 0.06 | 1.66 | 0.54 | (113.91) | — |
Debt/Assets |
44.55% | 31.87% | 27.27% | 16.35% | 7.52% | 7.11% | 0.00% | 85.96% | 0.00% |
Debt/Equity |
(1.26) | 4.79 | 0.96 | 0.33 | 0.31 | 1.64 | 0.00 | 6.28 | — |
Asset Turnover |
0.22 | 0.39 | 0.08 | 0.04 | 0.05 | 0.04 | 0.00 | 0.00 | — |
Operating CF/Net income |
0.14 | 0.11 | 0.20 | (9.72) | 1.10 | 0.30 | (0.19) | 0.45 | — |
Capex/Depreciation |
0.00 | (0.02) | (0.01) | (0.40) | (0.70) | (0.20) | — | — | — |
Interest Coverage |
(9.08) | (6.12) | (63.78) | (70.14) | (34.39) | (64.54) | (0.45) | — | — |
| 628.23% | (232.51%) | (163.67%) | 9.51% | 46.35% | 79.12% | 234.03% | 0.00% | — | |
| (76.50%) | (41.86%) | (72.04%) | 3.48% | (23.69%) | (57.63%) | 4.03% | (1.26%) | — | |
ROIC |
(1,070.92%) | (47.58%) | (150.27%) | (6.39%) | (73.05%) | 0.00% | (25.77%) | (0.46%) | — |
Return on Tangible Assets |
726.09% | (203.27%) | (965.88%) | 30.15% | (81.07%) | (153.61%) | 753.60% | 0.87% | — |
Average Days of Receivables |
63.97 | 91.26 | 194.24 | 141.45 | 89.53 | 167.44 | — | — | — |
Research and Development Expense of Revenue |
56.59% | 32.07% | 133.79% | 435.96% | 414.12% | 369.15% | — | — | — |
Selling, General and Administrative Expense of Revenue |
193.09% | 108.16% | 222.11% | 367.29% | 334.38% | 219.47% | 0.00% | 0.00% | — |
Intangible Assets out of Total Assets |
0.14 | 0.13 | 0.13 | 0.60 | 0.60 | 0.58 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
39.09% | 21.34% | 65.95% | 88.21% | 187.53% | 30.61% | 0.00% | — | — |
Graham Net Nets |
(4.68) | (2.27) | (1.67) | (1.07) | (0.74) | (1.68) | — | — | — |
Graham Number |
10.95 | 0.00 | 0.00 | 17.77 | 0.00 | 856.71 | — | — | — |
Earnings Yield |
(323.11%) | (127.40%) | (392.81%) | 8.73% | (110.33%) | (102.78%) | — | — | — |
Free Cash Flow Yield |
(47.21%) | (14.41%) | (79.66%) | (90.52%) | (33.87%) | (31.19%) | — | — | — |
Revenue per Share |
1.04 | 2.48 | 1.28 | 1.28 | 3.18 | 7.75 | 0.00 | 0.00 | — |
Operating CF per Share |
(0.52) | (0.29) | (2.17) | (9.85) | (16.42) | (34.31) | (1.21) | 0.00 | — |
Capex per Share |
0.00 | (0.01) | (0.06) | (0.37) | (0.92) | (15.11) | 0.00 | 0.00 | — |
Free Cash Flow per Share |
(0.52) | (0.30) | (2.23) | (10.23) | (17.34) | (49.42) | (1.21) | 0.00 | — |
Cash per Share |
0.24 | 0.03 | 0.01 | 1.00 | 5.55 | 29.49 | 1.01 | 0.03 | — |
Shareholders Equity per Share |
(1.49) | 0.40 | 2.30 | 14.22 | 14.83 | 10.16 | 5.50 | 0.03 | — |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Book value per Share |
(1.49) | 0.40 | 2.30 | 14.22 | 14.83 | 10.16 | 5.50 | 0.03 | — |
Free Cash Flow |
(13.25) | (6.56) | (39.73) | (143.11) | (116.30) | (91.03) | (1.10) | 0.00 | — |
Working Capital |
(68.44) | (33.12) | (47.50) | (28.59) | 32.88 | 45.48 | 0.78 | (0.13) | — |
Capital Expenditures |
— | (0.16) | (1.05) | (5.24) | (6.20) | (27.83) | — | — | — |
Net Current Asset Value |
(133.07) | (103.28) | (83.14) | (168.66) | (255.61) | (340.13) | (285.60) | (0.13) | — |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
Capex to Sales |
0.00 | 0.00 | 0.05 | 0.29 | 0.29 | 1.95 | — | — | — |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | — | — |
| Other line items | |||||||||
Depreciation/Fixed assets |
0.13 | 0.13 | 1.79 | 0.17 | 0.10 | 1.53 | — | — | — |
Cash ROIC |
(83.21%) | (12.65%) | (49.40%) | (51.40%) | (69.31%) | (87.81%) | (18.55%) | (0.25%) | — |
Accounts Receivable Turnover |
2.92 | 4.22 | 2.39 | 2.95 | 3.62 | 2.42 | — | — | — |
Accounts Payable Turnover |
0.81 | 0.80 | 1.61 | 2.60 | 1.31 | 1.76 | 0.00 | 0.00 | — |
Inventory Turnover |
6.71 | 2.69 | 2.90 | 2.65 | 1.44 | 0.74 | — | — | — |
Average Days of Payables |
480.42 | 567.29 | 322.34 | 107.84 | 352.30 | 398.90 | 0.00 | 0.00 | — |
Days of Inventory on Hand |
10.38 | 131.72 | 131.11 | 98.52 | 361.07 | 284.93 | — | — | — |
Average Receivables |
9.11 | 12.84 | 9.54 | 6.10 | 5.89 | 5.89 | — | — | — |
Average Payables |
24.86 | 18.72 | 9.98 | 7.56 | 7.35 | 2.80 | 0.11 | 0.11 | — |
Average Inventory |
2.99 | 5.58 | 5.53 | 7.43 | 6.70 | 6.70 | — | — | — |
Average Assets |
120.01 | 138.29 | 272.48 | 407.60 | 422.57 | 361.31 | 145.89 | 0.09 | — |
Average Common Equity |
(14.61) | 24.90 | 119.93 | 149.16 | (215.99) | (263.20) | 2.51 | 131.71 | — |
Columns are period end dates · fundamentals updated 1 Oct 2026